Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
AssigneeGenentech, Inc.
InventorsNapoleone FERRARA, Nina KORSISAARI, Robert D. MASS
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
Claims22
A method of reducing the risk of occurrence or delaying the occurrence of cancer in a subject, wherein said subject does not have cancer, said method comprising administering to said subject an effective amount of a VEGF-specific antagonist.
Dependencies are inferred from the claim text.